Table 1

Characteristics of the multiple sclerosis (MS) study population

Characteristics at the index dateStudy population
n=6793
Women, N (%)4999 (73.6)
Age (years), mean (SD)45.4 (13.3)
SES, N (%)
  1 (lowest income quintile)1199 (17.7)
  21303 (19.2)
  31411 (20.8)
  41468 (21.6)
  5 (highest income quintile)1385 (20.4)
  Unavailable27 (0.4)
Comorbidities*, N (%)
  Diabetes364 (5.4)
  Malignancies475 (7.0)
  Chronic lung diseases628 (9.2)
  Inflammatory bowel disease72 (1.1)
  Rheumatoid arthritis160 (2.4)
  Psoriasis22 (0.3)
Number of comorbidities*, N (%)
  None5306 (78.1)
  11277 (18.8)
  2 or more210 (3.1)
Follow-up time (years), median (IQR)8.5 (4.6–12.7)
Ever exposed†
  Any DMT, N (%)1716 (25.3)
First-generation DMTs
  Beta-interferon, N (%)1386 (20.4)
  Glatiramer acetate, N (%)656 (9.7)
Second-generation DMTs
  Natalizumab, N (%)100 (1.5)
  Oral DMTs, N (%)98 (1.4)
   Fingolimod, N (%)61 (0.9)
   Dimethyl fumarate, N (%)40 (0.6)
Number of people with ≥1
  Infection-related physician claim5765 (84.9)
  Infection-related hospitalisation726 (10.7)
  • *Comorbidities identified during the 5 years prior to index date (diabetes, malignancies, chronic lung disease, inflammatory bowel disease, rheumatoid arthritis and psoriasis); all were included to generate the ‘number of comorbidities’ shown in the table.

  • †No individual filled a prescription for teriflunomide, alemtuzumab or the generic beta-interferon-1b (Extavia) during the study period. As 458 individuals filled a prescription for more than one DMT group during the study period, the summed subgroups exceeds the total ever exposed (n=1716).

  • DMT, disease-modifying treatment; SES, socioeconomic status.